Sep 27, 2022 | News
Calgary, Alberta, Canada, September 26, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today announced that its board of directors has approved the grant of...
Aug 31, 2022 | News
CALGARY, Alberta – (August 31, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD), two programs its lead asset, MB-204 are...
Aug 9, 2022 | News
Calgary, Alberta, Canada, August 9, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or“Marvel”), is pleased to report that, further to its news releases of June 21, 2022 and...
Jul 25, 2022 | News
CALGARY, Alberta – (July 21, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204. The formulation...
Jul 18, 2022 | News
Calgary, Alberta, Canada, July 18, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to report that, further to its news release of June 21, 2022, it has...
Jun 22, 2022 | News
Calgary, Alberta, Canada, June 21, 2022 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a proposed non-brokered private placement of units (the...
